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Background
Cenderitide, also known as CD-NP, is a novel Mayo engi-
neered designer natriuretic peptide (NP), which unlike
native ANP, BNP and CNP co-activates both the guanylyl
(GC)-A receptor to which ANP and BNP bind and GC-B
to which CNP binds. Recognizing the aldosterone suppres-
sing actions of GC-A activation and the potent inhibition of
collagen synthesis and proliferation on fibroblasts to GC-B
activation we hypothesized cenderitide would be a potent
anti-fibrotic therapeutic agent. Here we defined the actions
of chronic cenderitide administrated subcutaneously by
pump in two models of cardiorenal fibrosis which included
in a model of post myocardial infarction (MI) induced car-
diorenal fibrosis and also in a model of chronic kidney dis-
ease produced by uninephrectomy (UNX).
Methods
Cenderitide was administered for 2 weeks (170 ng/kg/
min, Nile Therapeutics) with an osmotic pump follow-
ing MI (n=10) or UNX (n=10) while the control groups
received vehicle. Cardiorenal function and structure
were assessed 3 to 4 weeks after MI or UNX.
Results
Cardiorenal fibrosis was markedly suppressed by cenderi-
tide in both models of fibrosis. Specifically, following MI,
collagen content was decreased in the LV (MI:5±0.6, CD-
NP:3.5±0.4 %, p<0.05), and also in the renal cortex and
medulla (MI:3.5±0.5, CD-NP:1.3±0.3, p=0.002 and MI:19
±5 vs CD-NP:1.2±0.3 %, p=0.0006). After UNX, CD-NP
suppressed LV fibrosis vs. UNX (UNX: 4.2±0.5, CD-NP:3
±0.4%, p<0.05) and reduced medullary fibrosis. CD-NP
reduced aldosterone in the MI group (MI:39.4±10,
CDNP: 15±1 dl/ml, p=0.036) as well in the UNX group
(UNX: 30.4±6, CD-NP: 12.6±1.8 ng/dL, p<0.05). Impor-
tantly, proteinuria was also significantly reduced in CD-
NP (p<0.001) in both the MI and UNX group.
Conclusion
Cenderitide is a novel designer NP that acts as a potent
cardiorenal fibro-inhibiting therapeutic agent. It inhibits
cardiorenal fibrosis, suppresses aldosterone and reduces
proteinuria in two models of cardiorenal fibrosis. These
studies support chronic SQ CD-NP as an innovative
anti-fibrotic therapeutic.
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